Biohaven Ltd. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Biohaven Ltd. (BHVN) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$783.27 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-02
- Biohaven Ltd. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$783.27M.
- Biohaven Ltd. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$885.51M.
- Biohaven Ltd. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$424.65M.
- Biohaven Ltd. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$598.05M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$783.27M 10-K · filed 2026-03-02 |
| 2024-12-31 | -$885.51M 10-K · filed 2026-03-02 |
| 2023-12-31 | -$424.65M 10-K · filed 2026-03-02 |
| 2022-12-31 | -$598.05M 10-K · filed 2025-03-03 |
| 2021-12-31 | -$211.33M 10-K · filed 2024-02-29 |
| 2020-12-31 | -$123.47M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |